Prohost Biotech
HomeArticlesImpacting NewsVertex Pharmaceuticals Reports First Quarter 2024 Financial Results
Impacting News
Premium

Vertex Pharmaceuticals Reports First Quarter 2024 Financial Results

Vertex Pharmaceuticals Vertex Pharmaceuticals ( VRTX ) reported consolidated financial 2024 results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. Reshma...
P

Prohost Biotech

1 min read
26
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

Alpine Immune Sciences (ALPN)
Vertex Pharmaceuticals (VRTX)

Comments (0)

Please sign in to join the discussion

Related Articles

Impacting News
Premium

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of   $191.2 million, representing 57% year-over-year growth   AUVELITY ®   1Q 2026 net product sales of   $153.2 million, representing 59% year-over-year growth   SUN...
P

Prohost Biotech

May 6, 2026

1m
260
Impacting News
Premium

Neurocrine Biosciences Acquires Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

Neurocrine ...
P

Prohost Biotech

Apr 8, 2026

1m
197
Impacting News
Premium

FDA Approved Lilly's Foundayo™ (orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Without Food or Water Restrictions

Eli Lilly in the NEWS INDIANAPOLIS, April 1, 2026 /PRNewswire/, Eli Lilly and Company ( LLY ) , announced the U.S. FDA approved Foundayo™ (orforglipron) for adults with obesity, or overweight with wei...
P

Prohost Biotech

Apr 2, 2026

1m
234